U.S. Stem Cell, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by MURPHY WILLIAM P JR, was filed 25 Aug 2017.
U.S. Stem Cell, Inc.: what insiders have been doing
U.S. Stem Cell, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for U.S. Stem Cell, Inc. The previous disclosure was published on 29 April 2022.
Looking back to 2008, when coverage begins, insiders filed 57 purchases and 62 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -99.7%Entry US$0.92 · Close at T+365 US$0.00
- -99.2%Entry US$5.40 · Close at T+365 US$0.05
- -68.6%Entry US$57.00 · Close at T+365 US$17.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
- 2,500,000 shares@ US$0.004100.0% of flowCommon StockSEC:0001185185-22-000518:0
- 25,000,000 shares@ €0.007287.7% of flowCommon StockSEC:0001185185-22-000329:0
- 2,035,820 shares@ US$0.0045Common StockSEC:0001185185-21-001026:1
- 187,575 shares@ US$0.0487Common StockSEC:0001185185-21-001026:2
- 1,445,647 shares@ US$0.0063.9% of flowCommon StockSEC:0001185185-21-001026:0
- 7,518,797 shares@ €0.022350.0% of flowCommon StockSEC:0001185185-21-001028:0
- 526,918 shares@ US$0.027Common StockSEC:0001185185-18-001879:0
- 1,799,614 shares@ US$0.0277Common StockSEC:0001185185-17-001860:0Canonical exit: 15 Nov 2017 (T+90)
- 1,748,947 shares@ US$0.0335Common StockSEC:0001185185-17-000739:0
- 1,200,000 shares@ US$0.02Common StockSEC:0001185185-17-000594:0Canonical exit: 4 Jun 2017 (T+90)
- 14,606 sharesCommon StockSEC:0001185185-16-003718:0
- 219,155 sharesCommon StockSEC:0001185185-16-003483:0
- 55,056 sharesCommon StockSEC:0001185185-16-003483:1
- 2,150 sharesCommon StockSEC:0001185185-16-003406:0
- 900 sharesCommon StockSEC:0001185185-16-003406:1
- 1,850 sharesCommon StockSEC:0001185185-16-003406:2
- 300 sharesCommon StockSEC:0001185185-16-003406:3
- 5,775 sharesCommon StockSEC:0001185185-15-003376:0
- 1,150 sharesCommon StockSEC:0001185185-15-003376:1
- 600 sharesCommon StockSEC:0001185185-15-003376:2
- 1,514 sharesCommon StockSEC:0001185185-15-003350:0
- 950 sharesCommon StockSEC:0001185185-15-003351:4
- 1,300 sharesCommon StockSEC:0001185185-15-003351:5
- 146 shares@ US$0.7494Common StockSEC:0001185185-15-003351:0
- 1,250 sharesCommon StockSEC:0001185185-15-003351:1
25 of 159 declarations
About U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. is a U.S.-based healthcare and biotechnology company focused on regenerative medicine and cell therapy. For investors, it is best viewed as a small-cap, high-risk biotechnology story in the United States market; the company has historically been associated with OTC trading rather than a large-cap NYSE or NASDAQ listing, and its corporate footprint has been centered in Sunrise, Florida. Founded in 1999, the company was formerly known as Bioheart, Inc., and later rebranded to U.S. Stem Cell to better reflect its emphasis on stem-cell and cellular-therapy applications.
The company’s core business has centered on the discovery, development, and commercialization of autologous and cell-based therapies, especially in cardiovascular and regenerative-medicine use cases. Its flagship historical product candidate, MyoCell, is an autologous muscle stem-cell therapy intended to help improve cardiac function after serious heart damage. Public disclosures also show a broader business mix over time: physician training, cell collection and storage services, treatment kits, and clinic operations tied to regenerative medicine. That blend of R&D and service revenue has made the company more diversified than a pure development-stage biotech, but also exposed it to operational complexity.
Read moreShow less
From a competitive standpoint, U.S. Stem Cell operates in a niche but crowded field. It competes with better-capitalized biotech companies, specialty regenerative-medicine providers, and clinic-based service operators. Its differentiation has historically come from its proprietary therapy concepts, clinical know-how, and physician-facing ecosystem. For investors in France, Belgium, and Switzerland, this is important: the company is not a mainstream large pharmaceutical group, but rather a speculative healthcare micro-cap whose valuation is usually driven by regulatory progress, clinical execution, access to capital, and the ability to convert intellectual property into commercial adoption.
Geographically, the business has been primarily U.S.-based, with Florida as its main operational hub, while some training and commercialization efforts have been positioned for broader international reach. Recent public material continues to describe the company as focused on regenerative medicine and cellular therapeutics; however, as with many small biotech names, investors should assume elevated uncertainty around timing, funding, and commercialization. On the U.S. equity market, U.S. Stem Cell remains a name to monitor closely for corporate developments, including SEC Form 4 insider transaction activity and any changes in its reporting or exchange status.
